Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) Amend Collaboration for Development, Manufacturing and Commercialization of CTX001 in Sickle Cell Disease and Beta Thalassemia

CRISPR Therapeutics (CRSP) PT Raised to $189 at Oppenheimer on Revised Vertex Deal

Oppenheimer analyst Jay Olson raised the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $189.00 (from $187.00) while maintaining an Outperform rating on the amended Vertex deal.

The analyst commented, "CRSP/VRTX announced the revised collaboration agreement on CTX001 in SCD and TDT. Under... More

CRISPR Therapeutics' (CRSP) Restructured Vertex (VRTX) Deal 'Fantastic', Analyst Says

Shares of CRISPR Therapeutics (NASDAQ: CRSP) gained 3% in mid-day trading Tuesday after the company amended their collaboration agreement with Vertex Pharmaceuticals (NASDAQ: VRTX) for CTX001, an investigational CRISPR/Cas9-based gene editing therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT).

Under the terms of the restructured deal, Vertex will lead the global... More

CRISPR Therapeutics (CRSP) PT Raised to $117 at RBC Capital

RBC Capital analyst Luca Issi raised the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $117.00 (from $110.00) while maintaining a Sector Perform rating on restructured deal with VRTX.